Evidence map›Paper›PMID 35988658›Full record

ArticleGastroenterology2022

Enterohepatic Shunt-Driven Cholemia Predisposes to Liver Cancer.

Beng San Yeoh, Piu Saha, Rachel M Golonka, Jun Zou, Jessica L Petrick, Ahmed A Abokor, Xia Xiao, Venugopal R Bovilla, Alexis C A Bretin, Jesús Rivera-Esteban and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in Gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Elevated circulating bile acids driven erythrocyte osmotic resistance marks hepatobiliary disease.American journal of physiology. Gastrointestinal and liver physiology · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. [Research advances in occurrence risk assessment and early-stage diagnosis of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 2 countries.

Beng San YeohDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
Piu SahaDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
Rachel M GolonkaDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
Jun ZouCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia.
Jessica L PetrickSlone Epidemiology Center, Boston University, Boston, Massachusetts.
Ahmed A AbokorDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
Xia XiaoDivision of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Venugopal R BovillaDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
Alexis C A BretinCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia.
Jesús Rivera-EstebanLiver Unit, Department of Internal Medicine, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Dominick ParisiInformation Management Services, Rockville, Maryland.
Andrea A FlorioDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Stephanie J WeinsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Gordon J FreemanDepartment of Medical Oncology, Harvard Medical School, Boston, Massachusetts.
Amira F GoharaDepartment of Pathology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
Andreea CiudinEndocrinology and Nutrition Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Juan M PericàsLiver Unit, Department of Internal Medicine, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Bina JoeDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
Robert F SchwabeDepartment of Medicine, Columbia University Irving Medical Center, New York, New York.
Katherine A McGlynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Andrew T GewirtzCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia.
Matam Vijay-KumarDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio. Electronic address: MatamVijay.Kumar@Utoledo.edu.
University of Toledo · USGeorgia State University · USHarvard University · USNational Institutes of Health · USVall d'Hebron Institut de Recerca · ESBoston University · USColumbia University Irving Medical Center · USInformation Management Services · US

Funding

Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4M
Studies of Rare CancersZIACP010158 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MCGLYNN, KATHERINE · 2009 to 2025
$19.1M
The Organoid and Cell Culture CoreP30DK132710 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Robert F. Schwabe · 2022 to 2026
$7.2M
Pathophysiology of TLR5KO ColitisR01DK083890 · NIDDK · GEORGIA STATE UNIVERSITY · PI GEWIRTZ, ANDREW T · 2010 to 2023
$5.0M
DECONSTRUCTING INFLAMMATION AND ALTERED MICROBIOTA IN METABOLIC SYNDROMER01DK099071 · NIDDK · GEORGIA STATE UNIVERSITY · PI GEWIRTZ, ANDREW T · 2013 to 2024
$4.8M
Interplay between Dietary Fiber and Gut Microbiota in Hepatocellular CarcinomaR01CA219144 · NCI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI VIJAY-KUMAR, MATAM · 2017 to 2021
$1.6M
NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA219144NIDDK NIH HHS P30 DK132710NIDDK NIH HHS R01 DK083890NIDDK NIH HHS R01 DK099071
6 · The paper itself

Abstract

BACKGROUND &

aimsPathogenesis of hepatocellular carcinoma (HCC), which kills millions annually, is poorly understood. Identification of risk factors and modifiable determinants and mechanistic understanding of how they impact HCC are urgently needed.

methodsWe sought early prognostic indicators of HCC in C57BL/6 mice, which we found were prone to developing this disease when fed a fermentable fiber-enriched diet. Such markers were used to phenotype and interrogate stages of HCC development. Their human relevance was tested using serum collected prospectively from an HCC/case-control cohort.

resultsHCC proneness in mice was dictated by the presence of congenitally present portosystemic shunt (PSS), which resulted in markedly elevated serum bile acids (BAs). Approximately 10% of mice from various sources exhibited PSS/cholemia, but lacked an overt phenotype when fed standard chow. However, PSS/cholemic mice fed compositionally defined diets, developed BA- and cyclooxygenase-dependent liver injury, which was exacerbated and uniformly progressed to HCC when diets were enriched with the fermentable fiber inulin. Such progression to cholestatic HCC associated with exacerbated cholemia and an immunosuppressive milieu, both of which were required in that HCC was prevented by impeding BA biosynthesis or neutralizing interleukin-10 or programmed death protein 1. Analysis of human sera revealed that elevated BA was associated with future development of HCC.

conclusionsPSS is relatively common in C57BL/6 mice and causes silent cholemia, which predisposes to liver injury and HCC, particularly when fed a fermentable fiber-enriched diet. Incidence of silent PSS/cholemia in humans awaits investigation. Regardless, measuring serum BA may aid HCC risk assessment, potentially alerting select individuals to consider dietary or BA interventions.

Indexed as

Carcinoma, HepatocellularDigestive System DiseasesLiver NeoplasmsAnimalsDietary FiberHumansMiceMice, Inbred C57BLProstheses and ImplantsDietary FiberBile AcidsCholestasisHepatocellular CarcinomaImmunosuppressionPortosystemic Shunt

Identifiers

PMID35988658
PMCPMC9691575
OpenAlexW4292241851

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.